trial · primary record
Tozorakimab
Asthma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 540 |
| Primary completion | 2028-02-28 |
| Primary endpoint | Annualised rate of severe asthma exacerbations |
| Registry ID | NCT06932263 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:42:50.988Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06932263
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Tozorakimab · compound